Glaucoma Market

Global Glaucoma Market Size, Trends, & Analysis - Forecasts to 2028 By Disease Type (Open Angle Glaucoma, Angle Closure Glaucoma, Others), By Drug Class (Prostaglandins Analogs, Beta-Blockers, Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Others), By Distribution Channel Type (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on November 16 2024 with the latest and most recent market numbers

Global Glaucoma Market Size

The global glaucoma market is projected to grow at a CAGR of 5.0% from 2023 to 2028.

The market is primarily driven by the increasing prevalence of glaucoma due to aging population and lifestyle changes, coupled with a growing awareness of the condition among patients and healthcare professionals. Furthermore, advancements in diagnostic technologies, such as optical coherence tomography (OCT) and visual field testing, aid in early detection and accurate monitoring of the disease's progression.

In addition, ongoing research and development efforts focused on novel treatment options, including pharmaceuticals, minimally invasive surgeries, and innovative medical devices, which are aimed at improving patient outcomes and enhancing the overall quality of life for those living with glaucoma, are expected to greatly influence the market growth in the forecast period.

Furthermore, collaborations between pharmaceutical companies and academic institutions help accelerate the development of innovative therapeutic interventions, while governments and healthcare organizations are increasingly prioritizing the management of glaucoma through awareness campaigns and support for research initiatives. For instance, in January 2023, Bausch + Lomb announced a collaboration with the nonprofit Glaucoma Research Foundation (GRF) to launch a new eye health campaign in the U.S. The objective of this campaign is to share educational resources about glaucoma while raising awareness of the eye condition. Such initiatives are anticipated to significantly boost market revenue in the coming years.

However, limited access to healthcare in some countries, high treatment costs, and clinical challenges related to patient compliance with prescribed therapies remained obstacles to the glaucoma market growth. Nonetheless, the market players continue to make focused efforts to mitigate the impact of various market challenges and drive the market at a notable CAGR.

global glaucoma market

Global Glaucoma Market: By Disease Type

With a revenue share of over 50%, the open-angle glaucoma segment is the largest segment in the 2022 glaucoma market. This is mainly attributed to the increasing prevalence of open-angle glaucoma among the aging population. As the global population continues to age, the incidence of glaucoma is expected to rise, leading to a higher demand for effective treatment options.

Furthermore, advancements in medical technology and innovations in glaucoma diagnostics & therapeutics contribute significantly to the market's expansion. For instance, in March 2023, Sight Sciences, Inc., an eyecare technology company, announced the launch of its Ergo-series of the OMNI surgical system in the U.S., to facilitate minimally invasive, implant-free glaucoma procedures by surgeons in adults with primary open-angle glaucoma. These innovations aimed at efficient management of the condition, thereby enhancing patient outcomes and quality of life.

Global Glaucoma Market: By Drug Class Type

The prostaglandins analogs segment dominated the market with the highest revenue share in 2022 and is expected to have a high growth rate during the forecast period. This is mainly attributed to its established efficacy and widespread usage coupled with availability of clinical evidence for safety & effectiveness. They have been widely prescribed for glaucoma, establishing a strong track record of safety and efficacy.

On the other hand, adrenergic agonists are expected to grow at remarkable CAGR during the forecast period owing to the increasing regulatory approvals of drugs coupled with their improving effectiveness in glaucoma management. For instance, in April 2023, Alembic Pharmaceuticals Limited announced final clearance from the U.S. FDA for its Abbreviated New Drug Application (ANDA) Brimonidine Tartrate Ophthalmic Solution. The drug is an alpha-adrenergic receptor agonist formulated for the treatment of reduced elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Global Glaucoma Market: By Distribution Channel Type

The online pharmacy segment is projected to have high growth rate during the forecast period. Increasing prevalence of glaucoma has led to a higher demand for glaucoma medications and treatments. For long-term management of eye condition, patients often seek the convenience and accessibility offered by online pharmacies to refill their prescriptions promptly.

Furthermore, technological advancements and the widespread use of the internet have revolutionized the way people access healthcare services. Online pharmacies provide a user-friendly platform for consumers to purchase glaucoma medications from the comfort of their homes, eliminating the need for physical visits to traditional brick-and-mortar pharmacies. This convenience factor appeals to both patients and caregivers, especially those with mobility limitations or residing in remote areas.

asia pacific glaucoma market

Global Glaucoma Market: By Region

North America accounts for the major revenue share in the 2022 global glaucoma market. This is primarily attributed to the continuous approval of new drugs from the U.S. FDA. For instance, in September 2022, Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. announced FDA approval for OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002% eye drops which is designed in collaboration with UBE Corporation for the treatment of reduced elevated intraocular pressure in patients with ocular hypertension or primary open-angle glaucoma.

Furthermore, advancements in medical technology and treatment options have a profound impact on the market. Innovations such as minimally invasive surgeries, novel drug therapies, and more precise diagnostic tools have improved the management of glaucoma, leading to better patient outcomes. Additionally, the rising awareness of glaucoma and its potential consequences has prompted earlier diagnosis and intervention, positively impacting market growth.

Asia Pacific is anticipated to grow at the fastest CAGR during the forecast period, this is majorly attributed to improving healthcare infrastructure and rising awareness about eye health in the Asia Pacific region. Growing access to healthcare facilities and the adoption of advanced technologies for early diagnosis and treatment have led to better management of glaucoma cases, positively impacting the market's expansion.

Moreover, ongoing advancements in medical research and technology have resulted in the development of innovative glaucoma therapies. These cutting-edge treatment options, including minimally invasive surgeries and novel drug formulations, have opened new avenues for market players, attracting investment and driving further market growth.

Global Glaucoma Share and Competitor Analysis

Pfizer Inc., Santen Pharmaceutical Co., Ltd., Novartis AG, Alcon Inc., Akron Operating Company LLC, Thea Pharma, AbbVie, Inc., Bausch + Lomb Corporation, and Teva Pharmaceuticals Industries Ltd., among others, are some key players in the global glaucoma market.

Please note: This is not an exhaustive list of companies profiled in the report.

Apart from new product development, the other most widely adopted approach undertaken by the key players in the market is merger and acquisition. For instance, in August 2022, Alcon announced to acquire Aerie Pharmaceuticals, Inc., a pharmaceutical company that is engaged in the development of first-in-class ophthalmic therapies. This acquisition is expected to boost Alcon’s business operations in the ophthalmic pharmaceutical space by adding broader pharmaceutical R&D capabilities.

1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS

1.1 Strategic Opportunity & Attractiveness Analysis

1.1.1 Hot Revenue Pockets

1.1.2 Market Attractiveness Score

1.1.3 Revenue Impacting Opportunity

1.1.4 High-Growing Region/Country

1.1.5 Competitor Analysis

1.1.6 Consumer Analysis

1.2 Global Market Estimates' View

1.3 Strategic Insights Across Business Functions

1.3.1 For Chief Executive Officers

1.3.2 For Chief Marketing Officers

1.3.3 For Chief Strategy Officers

1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into

2 TECHNOLOGICAL TRENDS

2.1 Technological Adoption Rate

2.2 Current Trend Impact Analysis

2.3 Future Trend Impact Analysis

3 GLOBAL MARKET OUTLOOK

3.1 Market Pyramid Analysis

3.1.1 Introduction

3.1.2 Adjacent Market Opportunities

3.1.3 Ancillary Market Opportunities

3.2 Demand Side Analysis

3.2.1 Market Drivers: Impact Analysis

3.2.2 Market Restraints: Impact Analysis

3.2.3 Market Opportunities: Impact Analysis

3.2.4 Market Challenges: Impact Analysis

3.3 Supply Side Analysis

3.3.1 Porter’s Five Forces Analysis

3.3.1.1 Threat of New Entrants

3.3.1.2 Threat of New Substitutes

3.3.1.3 Bargaining Power of Suppliers

3.3.1.4 Bargaining Power of Buyers

3.3.1.5 Intensity of Competitive Rivalry

3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)

3.3.2.1 Political Landscape

3.3.2.2 Economic Landscape

3.3.2.3 Social Landscape

3.3.2.4 Technology Landscape

3.3.3 Value Chain Analysis

3.3.4 Trend Analysis

4 GLOBAL GLAUCOMA MARKET, BY DISEASE TYPE

4.1 Introduction

4.2 Glaucoma market: Technology Scope Key Takeaways

4.3 Revenue Growth Analysis, 2022 & 2028

4.4 Open Angle Glaucoma

4.4.1 Open Angle Glaucoma Market Estimates and Forecast, 2020-2028 (USD Million)

4.5 Angle Closure Glaucoma

4.5.1 Angle Closure Glaucoma Market Estimates and Forecast, 2020-2028 (USD Million)

4.5 Others

4.5.1 Others Market Estimates and Forecast, 2020-2028 (USD Million)

5 GLOBAL GLAUCOMA MARKET, BY DRUG CLASS TYPE

5.1 Introduction

5.2 Glaucoma market: Drug Class Type Scope Key Takeaways

5.3 Revenue Growth Analysis, 2022 & 2028

5.4 Prostaglandin Analogs

5.4.1 Prostaglandin Analogs Market Estimates and Forecast, 2020-2028 (USD Million)

5.5 Beta-Blockers

5.5.1 Beta-Blockers Market Estimates and Forecast, 2020-2028 (USD Million)

5.6 Adrenergic Agonists

5.6.1 Adrenergic AgonistsMarket Estimates and Forecast, 2020-2028 (USD Million)

5.7 Carbonic Anhydrase Inhibitors

5.7.1 Carbonic Anhydrase Inhibitors Market Estimates and Forecast, 2020-2028 (USD Million)

5.8 Others

5.8.1 Others Market Estimates and Forecast, 2020-2028 (USD Million)

6 GLOBAL GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL TYPE

6.1 Introduction

6.2 Glaucoma market: Distribution Channel Type Scope Key Takeaways

6.3 Revenue Growth Analysis, 2022 & 2028

6.4 Hospital Pharmacy

6.4.1 Hospital Pharmacy Market Estimates and Forecast, 2020-2028 (USD Million)

6.5 Retail Pharmacy

6.5.1 Retail Pharmacy Market Estimates and Forecast, 2020-2028 (USD Million)

6.6 Online Pharmacy

6.5.1 Online Pharmacy Market Estimates and Forecast, 2020-2028 (USD Million)

7 GLOBAL GLAUCOMA MARKET, BY REGION

7.1 Introduction

7.2 North America Glaucoma Market Estimates and Forecast, 2020-2028 (USD Million)

7.2.1 By Disease Type

7.2.2 By Drug Class Type

7.2.3 By Distribution Channel Type

7.2.4 By Country

7.2.4.1 U.S. Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.1.1 By Disease Type

7.2.4.1.2 By Drug Class Type

7.2.4.1.3 By Distribution Channel Type

7.2.4.2 Canada Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.2.1 By Disease Type

7.2.4.2.2 By Drug Class Type

7.2.4.2.3 By Distribution Channel Type

7.2.4.3 Mexico Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.3.1 By Disease Type

7.2.4.3.2 By Drug Class Type

7.2.4.3.3 By Distribution Channel Type

7.3 Europe Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.3.1 By Disease Type

7.3.2 By Drug Class Type

7.3.3 By Distribution Channel Type

7.3.4 By Country

7.3.4.1 Germany Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.1.1 By Disease Type

7.3.4.1.2 By Drug Class Type

7.3.4.1.3 By Distribution Channel Type

7.3.4.2 U.K. Presered Flowers Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.2.1 By Disease Type

7.3.4.2.2 By Drug Class Type

7.3.4.2.3 By Distribution Channel Type

7.3.4.3 France Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.3.1 By Disease Type

7.3.4.3.2 By Drug Class Type

7.3.4.3.3 By Distribution Channel Type

7.3.4.4 Italy Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.4.1 By Disease Type

7.3.4.4.2 By Drug Class Type

7.3.4.4.3 By Distribution Channel Type

7.3.4.5 Spain Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.5.1 By Disease Type

7.3.4.5.2 By Drug Class Type

7.3.4.5.3 By Distribution Channel Type

7.3.4.6 Netherlands Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.6.1 By Disease Type

7.3.4.6.2 By Drug Class Type

7.3.4.6.3 By Distribution Channel Type

7.3.4.7 Rest of Europe Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.7.1 By Disease Type

7.3.4.7.2 By Drug Class Type

7.3.4.7.3 By Distribution Channel Type

7.4 Asia Pacific Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.1 By Disease Type

7.4.2 By Drug Class Type

7.4.3 By Distribution Channel Type

7.4.4 By Country

7.4.4.1 China Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.1.1 By Disease Type

7.4.4.1.2 By Drug Class Type

7.4.4.1.3 By Distribution Channel Type

7.4.4.2 Japan Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.2.1 By Disease Type

7.4.4.2.2 By Drug Class Type

7.4.4.2.3 By Distribution Channel Type

7.4.4.3 India Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.3.1 By Disease Type

7.4.4.3.2 By Drug Class Type

7.4.4.3.3 By Distribution Channel Type

7.4.4.4 South Korea Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.4.1 By Disease Type

7.4.4.4.2 By Drug Class Type

7.4.4.4.3 By Distribution Channel Type

7.4.4.5 Singapore Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.5.1 By Disease Type

7.4.4.5.2 By Drug Class Type

7.4.4.5.3 By Distribution Channel Type

7.4.4.6 Malaysia Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.6.1 By Disease Type

7.4.4.6.2 By Drug Class Type

7.4.4.6.3 By Distribution Channel Type

7.4.4.7 Thailand Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.7.1 By Disease Type

7.4.4.7.2 By Drug Class Type

7.4.4.7.3 By Distribution Channel Type

7.4.4.8 Indonesia Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.7.1 By Disease Type

7.4.4.7.2 By Drug Class Type

7.4.4.7.3 By Distribution Channel Type

7.4.4.9 Vietnam Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.8.1 By Disease Type

7.4.4.8.2 By Drug Class Type

7.4.4.8.3 By Distribution Channel Type

7.4.4.10 Taiwan Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.9.1 By Disease Type

7.4.4.9.2 By Drug Class Type

7.4.4.9.3 By Distribution Channel Type

7.4.4.11 Rest of Asia Pacific Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.11.1 By Disease Type

7.4.4.11.2 By Drug Class Type

7.4.4.11.3 By Distribution Channel Type

7.5 Middle East & Africa Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.5.1 By Disease Type Type

7.5.2 By Drug Class Type

7.5.3 By Distribution Channel Type

7.5.4 By Country

7.5.4.1 Saudi Arabia Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.1.1 By Disease Type

7.5.4.1.2 By Drug Class Type

7.5.4.1.3 By Distribution Channel Type

7.5.4.2 U.A.E. Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.2.1 By Disease Type

7.5.4.2.2 By Drug Class Type

7.5.4.2.3 By Distribution Channel Type

7.5.4.3 Israel Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.3.1 By Disease Type

7.5.4.3.2 By Drug Class Type

7.5.4.3.3 By Distribution Channel Type

7.5.4.4 South Africa Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.4.1 By Disease Type

7.5.4.4.2 By Drug Class Type

7.5.4.4.3 By Distribution Channel Type

7.5.4.5 Rest of Middle East & Africa Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.5.1 By Disease Type

7.5.4.5.2 By Drug Class Type

7.5.4.5.3 By Distribution Channel Type

7.6 Central & South America Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.6.1 By Disease Type

7.6.2 By Drug Class Type

7.6.3 By Distribution Channel Type

7.6.4 By Country

7.6.4.1 Brazil Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.6.4.1.1 By Disease Type

7.6.4.1.2 By Drug Class Type

7.6.4.1.3 By Distribution Channel Type

7.6.4.2 Argentina Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.6.4.2.1 By Disease Type

7.6.4.2.2 By Drug Class Type

7.6.4.2.3 By Distribution Channel Type

7.6.4.3 Chile Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.6.4.3.1 By Disease Type

7.6.4.3.2 By Drug Class Type

7.6.4.3.3 By Distribution Channel Type

7.6.4.4 Rest of Central & South America Glaucoma market Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.4.1 By Disease Type

7.2.4.4.2 By Drug Class Type

7.2.4.4.3 By Distribution Channel Type

8 COMPETITIVE LANDCAPE

8.1 Company Market Share Analysis

8.2 Four Quadrant Positioning Matrix

8.2.1 Market Leaders

8.2.2 Market Visionaries

8.2.3 Market Challengers

8.2.4 Niche Market Players

8.3.4 Rest of the World

8.4 Company Profiles

8.4.1 Pfizer Inc.

8.4.1.1 Business Description & Financial Analysis

8.4.1.2 SWOT Analysis

8.4.1.3 Products & Services Offered

8.4.1.4 Strategic Alliances between Business Partners

8.4.2 Santen Pharmaceutical Co., Ltd.

8.4.2.1 Business Description & Financial Analysis

8.4.2.2 SWOT Analysis

8.4.2.3 Products & Services Offered

8.4.2.4 Strategic Alliances between Business Partners

8.4.3 NOVARTIS AG

8.4.3.1 Business Description & Financial Analysis

8.4.3.2 SWOT Analysis

8.4.3.3 Products & Services Offered

8.4.3.4 Strategic Alliances between Business Partners

8.4.4 Alcon Inc.

8.4.4.1 Business Description & Financial Analysis

8.4.4.2 SWOT Analysis

8.4.4.3 Products & Services Offered

8.4.4.4 Strategic Alliances between Business Partners

8.4.5 Akron Operating Company LLC

8.4.5.1 Business Description & Financial Analysis

8.4.5.2 SWOT Analysis

8.4.5.3 Products & Services Offered

8.4.5.4 Strategic Alliances between Business Partners

8.4.6 THEA PHARMA

8.4.6.1 Business Description & Financial Analysis

8.4.6.2 SWOT Analysis

8.4.6.3 Products & Services Offered

8.4.6.4 Strategic Alliances between Business Partners

8.4.7 ABBVIE, INC.

8.4.7.1 Business Description & Financial Analysis

8.4.7.2 SWOT Analysis

8.4.7.3 Products & Services Offered

8.4.7.4 Strategic Alliances between Business Partners

8.4.8 Bausch + Lomb Corporation

8.4.7.1 Business Description & Financial Analysis

8.4.7.2 SWOT Analysis

8.4.7.3 Products & Services Offered

8.4.7.4 Strategic Alliances between Business Partners

8.4.9 Teva Pharmaceuticals Industries Ltd.

8.4.8.1 Business Description & Financial Analysis

8.4.8.2 SWOT Analysis

8.4.8.3 Products & Services Offered

8.4.8.4 Strategic Alliances between Business Partners

8.4.10 Cipla Incorporation

8.4.9.1 Business Description & Financial Analysis

8.4.9.2 SWOT Analysis

8.4.9.3 Products & Services Offered

8.4.9.4 Strategic Alliances between Business Partners

8.4.11 Other Companies

8.4.11.1 Business Description & Financial Analysis

8.4.11.2 SWOT Analysis

8.4.11.3 Products & Services Offered

8.4.11.4 Strategic Alliances between Business Partners

9 RESEARCH METHODOLOGY

9.1 Market Introduction

9.1.1 Market Definition

9.1.2 Market Scope & SegOrchidtation

9.2 Information ProcureOrchidt

9.2.1 Secondary Research

9.2.1.1 Purchased Databases

9.2.1.2 GMEs Internal Data Repository

9.2.1.3 Secondary Resources & Third Party Perspectives

9.2.1.4 Company Information Sources

9.2.2 Primary Research

9.2.2.1 Various Types of Respondents for Primary Interviews

9.2.2.2 Number of Interviews Conducted throughout the Research Process

9.2.2.3 Primary Stakeholders

9.2.2.4 Discussion Guide for Primary Participants

9.2.3 Expert Panels

9.2.3.1 Expert Panels Across 30+ Industry

9.2.4 Paid Local Experts

9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region

9.3 Market Estimation

9.3.1 Top-Down Approach

9.3.1.1 Macro-Economic Indicators Considered

9.3.1.2 Micro-Economic Indicators Considered

9.3.2 Bottom Up Approach

9.3.2.1 Company Share Analysis Approach

9.3.2.2 Estimation of Potential Product Sales

9.4 Data Triangulation

9.4.1 Data Collection

9.4.2 Time Series, Cross Sectional & Panel Data Analysis

9.4.3 Cluster Analysis

9.5 Analysis and Output

9.5.1 Inhouse AI Based Real Time Analytics Tool

9.5.2 Output From Desk & Primary Research

9.6 Research Assumptions & Limitations

9.7.1 Research Assumptions

9.7.2 Research Limitations

10 COMPETITIVE LANDCAPE

10.1 Company Market Share Analysis

10.2 Four Quadrant Positioning Matrix

10.2.1 Market Leaders

10.2.2 Market Visionaries

10.2.3 Market Challengers

10.2.4 Niche Market Players

10.3 Vendor Landscape

10.3.1 North America

10.3.2 Europe

10.3.3 Asia Pacific

10.3.4 Rest of the World

10.4 Company Profiles

10.4.1 Pfizer Inc.

10.4.1.1 Business Description & Financial Analysis

10.4.1.2 SWOT Analysis

10.4.1.3 Products & Services Offered

10.4.1.4 Strategic Alliances between Business Partners

10.4.2 Santen Pharmaceutical Co., Ltd.

10.4.2.1 Business Description & Financial Analysis

10.4.2.2 SWOT Analysis

10.4.2.3 Products & Services Offered

10.4.2.4 Strategic Alliances between Business Partners

10.4.3 NOVARTIS AG

10.4.3.1 Business Description & Financial Analysis

10.4.3.2 SWOT Analysis

10.4.3.3 Products & Services Offered

10.4.3.4 Strategic Alliances between Business Partners

10.4.4 Alcon Inc.

10.4.4.1 Business Description & Financial Analysis

10.4.4.2 SWOT Analysis

10.4.4.3 Products & Services Offered

10.4.4.4 Strategic Alliances between Business Partners

10.4.5 Akron Operating Company LLC

10.4.5.1 Business Description & Financial Analysis

10.4.5.2 SWOT Analysis

10.4.5.3 Products & Services Offered

10.4.5.4 Strategic Alliances between Business Partners

10.4.6 THEA PHARMA

10.4.6.1 Business Description & Financial Analysis

10.4.6.2 SWOT Analysis

10.4.6.3 Products & Services Offered

10.4.6.4 Strategic Alliances between Business Partners

10.4.7 ABBVIE, INC.

10.4.7.1 Business Description & Financial Analysis

10.4.7.2 SWOT Analysis

10.4.7.3 Products & Services Offered

10.4.7.4 Strategic Alliances between Business Partners

10.4.8 Bausch + Lomb Corporation

10.4.7.1 Business Description & Financial Analysis

10.4.7.2 SWOT Analysis

10.4.7.3 Products & Services Offered

10.4.7.4 Strategic Alliances between Business Partners

10.4.9 Teva Pharmaceuticals Industries Ltd.

10.4.9.1 Business Description & Financial Analysis

10.4.9.2 SWOT Analysis

10.4.9.3 Products & Services Offered

10.4.9.4 Strategic Alliances between Business Partners

10.4.10 Cipla Incorporation

10.4.10.1 Business Description & Financial Analysis

10.4.10.2 SWOT Analysis

10.4.10.3 Products & Services Offered

10.4.10.4 Strategic Alliances between Business Partners

10.4.11 Other Companies

10.4.11.1 Business Description & Financial Analysis

10.4.11.2 SWOT Analysis

10.4.11.3 Products & Services Offered

10.4.11.4 Strategic Alliances between Business Partners

LIST OF TABLES

1 Global Glaucoma market, By Disease Type, 2020-2028 (USD Mllion)

2 OPEN ANGLE GLAUCOMA Market, By Region, 2020-2028 (USD Mllion)

3 ANGLE CLOSURE GLAUCOMA Market, By Region, 2020-2028 (USD Mllion)

4 Others Market, By Region, 2020-2028 (USD Mllion)

5 Global Glaucoma market, By Drug Class Type, 2020-2028 (USD Mllion)

6 Prostaglandin analogs Market, By Region, 2020-2028 (USD Mllion)

7 Beta-Blockers Market, By Region, 2020-2028 (USD Mllion)

8 Adrenergic Agonists Market, By Region, 2020-2028 (USD Mllion)

9 Carbonic Anhydrase Inhibitors Market, By Region, 2020-2028 (USD Mllion)

10 Others Market, By Region, 2020-2028 (USD Mllion)

11 Global Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Mllion)

12 Hospital Pharmacy Market, By Region, 2020-2028 (USD Mllion)

13 Retail Pharmacy Market, By Region, 2020-2028 (USD Mllion)

14 online pharmacy Market, By Region, 2020-2028 (USD Mllion)

15 Regional Analysis, 2020-2028 (USD Mllion)

16 North America Glaucoma market, By Disease Type, 2020-2028 (USD Million)

17 North America Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

18 North America Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

19 North America Glaucoma market, By Country, 2020-2028 (USD Million)

20 U.S Glaucoma market, By Disease Type, 2020-2028 (USD Million)

21 U.S Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

22 U.S Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

23 Canada Glaucoma market, By Disease Type, 2020-2028 (USD Million)

24 Canada Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

25 Canada Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

26 Mexico Glaucoma market, By Disease Type, 2020-2028 (USD Million)

27 Mexico Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

28 Mexico Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

29 Europe Glaucoma market, By Disease Type, 2020-2028 (USD Million)

30 Europe Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

31 Europe Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

32 Germany Glaucoma market, By Disease Type, 2020-2028 (USD Million)

33 Germany Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

34 Germany Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

35 UK Glaucoma market, By Disease Type, 2020-2028 (USD Million)

36 UK Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

37 UK Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

38 France Glaucoma market, By Disease Type, 2020-2028 (USD Million)

39 France Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

40 France Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

41 Italy Glaucoma market, By Disease Type, 2020-2028 (USD Million)

42 Italy Glaucoma market, By Drug Class Type Type, 2020-2028 (USD Million)

43 Italy Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

44 Spain Glaucoma market, By Disease Type, 2020-2028 (USD Million)

45 Spain Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

46 Spain Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

47 Rest Of Europe Glaucoma market, By Disease Type, 2020-2028 (USD Million)

48 Rest Of Europe Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

49 Rest of Europe Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

50 Asia Pacific Glaucoma market, By Disease Type, 2020-2028 (USD Million)

51 Asia Pacific Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

52 Asia Pacific Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

53 Asia Pacific Glaucoma market, By Country, 2020-2028 (USD Million)

54 China Glaucoma market, By Disease Type, 2020-2028 (USD Million)

55 China Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

56 China Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

57 India Glaucoma market, By Disease Type, 2020-2028 (USD Million)

58 India Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

59 India Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

60 Japan Glaucoma market, By Disease Type, 2020-2028 (USD Million)

61 Japan Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

62 Japan Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

63 South Korea Glaucoma market, By Disease Type, 2020-2028 (USD Million)

64 South Korea Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

65 South Korea Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

66 Middle East & Africa Glaucoma market, By Disease Type, 2020-2028 (USD Million)

67 Middle East & Africa Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

68 Middle East & Africa Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

69 Middle East & Africa Glaucoma market, By Country, 2020-2028 (USD Million)

70 Saudi Arabia Glaucoma market, By Disease Type, 2020-2028 (USD Million)

71 Saudi Arabia Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

72 Saudi Arabia Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

73 UAE Glaucoma market, By Disease Type, 2020-2028 (USD Million)

74 UAE Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

75 UAE Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

76 Central & South America Glaucoma market, By Disease Type, 2020-2028 (USD Million)

77 Central & South America Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

78 Central & South America Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

79 Central & South America Glaucoma market, By Country, 2020-2028 (USD Million)

80 Brazil Glaucoma market, By Disease Type, 2020-2028 (USD Million)

81 Brazil Glaucoma market, By Drug Class Type, 2020-2028 (USD Million)

82 Brazil Glaucoma market, By Distribution Channel Type, 2020-2028 (USD Million)

83 Pfizer Inc.: Products & Services Offering

84 Santen Pharmaceutical Co., Ltd.: Products & Services Offering

85 NOVARTIS AG : Products & Services Offering

86 Alcon Inc.: Products & Services Offering

87 Akron Operating Company LLC: Products & Services Offering

88 THEA PHARMA: Products & Services Offering

89 ABBVIE, INC.: Products & Services Offering

90 Bausch + Lomb Corporation: Products & Services Offering

91 Teva Pharmaceuticals Industries Ltd.: Products & Services Offering

92 Cipla Incorporation: Products & Services Offering

93 Other Companies: Products & Services Offering

LIST OF FIGURES

1 Global Glaucoma market Overview

2 Global Glaucoma market Value From 2020-2028 (USD Mllion)

3 Global Glaucoma market Share, By Disease Type (2022)

4 Global Glaucoma market Share, By Drug Class Type (2022)

5 Global Glaucoma market Share, By Distribution Channel Type (2022)

6 Global Glaucoma market, By Region (Asia Pacific Market)

7 Technological Trends In Global Glaucoma market

8 Four Quadrant Competitor Positioning Matrix

9 Impact Of Macro & Micro Indicators On The Market

10 Impact Of Key Drivers On The Global Glaucoma market

11 Impact Of Challenges On The Global Glaucoma market

12 Porter’s Five Forces Analysis

13 Global Glaucoma market: By Disease Type Scope Key Takeaways

14 Global Glaucoma market, By Disease Type Segment: Revenue Growth Analysis

15 Open Angle Glaucoma Market, By Region, 2020-2028 (USD Mllion)

16 Angle Closure Glaucoma Market, By Region, 2020-2028 (USD Mllion)

17 Others Market, By Region, 2020-2028 (USD Mllion)

18 Global Glaucoma market: By Drug Class Type Scope Key Takeaways

19 Global Glaucoma market, By Drug Class Type Segment: Revenue Growth Analysis

20 Prostaglandin Analogs Market, By Region, 2020-2028 (USD Mllion)

21 Beta-Blockers Market, By Region, 2020-2028 (USD Mllion)

22 Adrenergic Agonists Market, By Region, 2020-2028 (USD Mllion)

23 Carbonic Anhydrase Inhibitors Market, By Region, 2020-2028 (USD Mllion)

24 Others Market, By Region, 2020-2028 (USD Mllion)

25 Global Glaucoma market: By Distribution Channel Type Scope Key Takeaways

26 Global Glaucoma market, By Distribution Channel Type Segment: Revenue Growth Analysis

27 Hospital Pharmacy Market, By Region, 2020-2028 (USD Mllion)

28 Retail Pharmacy Market, By Region, 2020-2028 (USD Mllion)

29 Online Pharmacy Market, By Region, 2020-2028 (USD Mllion)

30 Regional Segment: Revenue Growth Analysis

31 Global Glaucoma market: Regional Analysis

32 North America Glaucoma market Overview

33 North America Glaucoma market, By Disease Type

34 North America Glaucoma market, By Drug Class Type

35 North America Glaucoma market, By Distribution Channel Type

36 North America Glaucoma market, By Country

37 U.S. Glaucoma market, By Disease Type

38 U.S. Glaucoma market, By Drug Class Type

39 U.S. Glaucoma market, By Distribution Channel Type

40 Canada Glaucoma market, By Disease Type

41 Canada Glaucoma market, By Drug Class Type

42 Canada Glaucoma market, By Distribution Channel Type

43 Mexico Glaucoma market, By Disease Type

44 Mexico Glaucoma market, By Drug Class Type

45 Mexico Glaucoma market, By Distribution Channel Type

46 Four Quadrant Positioning Matrix

47 Company Market Share Analysis

48 Pfizer Inc.: Company Snapshot

49 Pfizer Inc.: SWOT Analysis

50 Pfizer Inc.: Geographic Presence

51 Santen Pharmaceutical Co., Ltd.: Company Snapshot

52 Santen Pharmaceutical Co., Ltd.: SWOT Analysis

53 Santen Pharmaceutical Co., Ltd.: Geographic Presence

54 NOVARTIS AG : Company Snapshot

55 NOVARTIS AG : SWOT Analysis

56 NOVARTIS AG : Geographic Presence

57 Alcon Inc.: Company Snapshot

58 Alcon Inc.: Swot Analysis

59 Alcon Inc.: Geographic Presence

60 Akron Operating Company LLC: Company Snapshot

61 Akron Operating Company LLC: SWOT Analysis

62 Akron Operating Company LLC: Geographic Presence

63 THEA PHARMA: Company Snapshot

64 THEA PHARMA: SWOT Analysis

65 THEA PHARMA: Geographic Presence

66 ABBVIE, INC. : Company Snapshot

67 ABBVIE, INC. : SWOT Analysis

68 ABBVIE, INC. : Geographic Presence

69 Bausch + Lomb Corporation: Company Snapshot

70 Bausch + Lomb Corporation: SWOT Analysis

71 Bausch + Lomb Corporation: Geographic Presence

72 Teva Pharmaceuticals Industries Ltd.: Company Snapshot

73 Teva Pharmaceuticals Industries Ltd.: SWOT Analysis

74 Teva Pharmaceuticals Industries Ltd.: Geographic Presence

75 Cipla Incorporation: Company Snapshot

76 Cipla Incorporation: SWOT Analysis

77 Cipla Incorporation: Geographic Presence

78 Other Companies: Company Snapshot

79 Other Companies: SWOT Analysis

80 Other Companies: Geographic Presence

The Global Glaucoma Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

Glaucoma Market Size

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Glaucoma Market.

Glaucoma Market Growth

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Glaucoma Market Trends

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

Glaucoma Market Share

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the Glaucoma market?

The global glaucoma market is projected to grow at a CAGR of 5.0% from 2023 to 2028.

Who are the major vendors in the Glaucoma market?

What are the opportunities prevailing in the global Glaucoma market?

As the global population continues to age, the prevalence of glaucoma is expected to rise, driving an increasing demand for innovative diagnostic tools and treatment options. One significant opportunity lies in the advancement of early detection and diagnosis technologies. Timely identification of glaucoma will significantly improve patient outcomes and reduce the risk of severe vision loss. Continuous research and development efforts will yield more accurate and accessible diagnostic tools, such as advanced imaging techniques and genetic testing, which will revolutionize glaucoma screening and monitoring. Moreover, the pharmaceutical industry is a promising prospect in developing novel and more effective therapies for glaucoma management.

What are the major drivers in the Glaucoma market?

Advancements in medical technology and innovative treatment options have contributed to the expansion of the glaucoma market. The development of minimally invasive glaucoma surgeries (MIGS) and novel pharmaceutical therapies have revolutionized glaucoma management, offering patients more effective and less invasive treatment alternatives. These advancements have improved patient outcomes and stimulated market growth through increased adoption and market penetration. Furthermore, growing awareness about the importance of early detection and regular eye examinations for glaucoma diagnosis has also impacted the market positively. Public health campaigns and initiatives aimed at educating the population about glaucoma risk factors and preventive measures have led to early diagnosis, enabling timely intervention and management of the disease, thereby boosting the demand for glaucoma products and services.